Clinical trials: Vision Therapy
Hypersensitivity
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever.
- Trial name
- NCT01569191
- Testing
- Artificial Tear Supplement, Cold compress, Anti-allergic Medication
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aston University
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Fungal Keratitis
Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
We evaluated whether voriconazole is a superior treatment to natamycin for filamentous fungal keratitis in a randomized, masked, controlled trial.
- Trial name
- MUTT_TE (NCT00557362)
- Testing
- Natamycin 5%, Voriconazole, Corneal de-epithelialization
- Where
- 2 sites in India
- Volunteers
- 120 people
- Sponsor
- University of California, San Francisco
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Glaucoma
Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma
To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.
- Trial name
- B350vsCP250 (NCT04542616)
- Testing
- Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- State University of New York at Buffalo
Amblyopia, Ocular Motility Disorders
A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming
The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive).
- Trial name
- ICARE (NCT03066063)
- Testing
- iCare, Amblyopia standard of Care, CI standard of Care
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barron Associates, Inc.
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
COPD
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD
Evidence from investigators' group has shown that chronic obstructive pulmonary disease (COPD) patients have impairment of antioxidant defenses which are caused by a defect in activity of Nrf2.
- Trial name
- BEST (NCT01335971)
- Testing
- Sulforaphane 25, Sulforaphane 150
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Johns Hopkins University
Cancer Pain, Opioid Use
Psychological Intervention Using Smartphone Technology to Alleviate Malignant Pain
The purpose of this study is to develop and pilot test a novel medical intervention (STAMP+CBT app) that will help patients track their pain, mood, opioid use and side effects while delivering tailored education and…
- Conditions
- Cancer Pain, Opioid Use, Cognitive Behavior Therapy
- Trial name
- STAMP+CBT (NCT05774197)
- Testing
- Cognitive Behavioral Therapy for pain
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Oklahoma
Glaucoma
Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
- Trial name
- Avastin (NCT00853073)
- Testing
- bevacizumab, balanced salt solution
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wills Eye
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Pseudophakia, Inflammation
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
- Trial name
- NCT01344226
- Testing
- loteprednol 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Toyos Clinic
Inflammation
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
- Trial name
- NCT00430092
- Testing
- Difluprednate
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Sirion Therapeutics, Inc.
Presbyopia, Near Vision
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia
- Conditions
- Presbyopia, Near Vision, Refractive Error, Eye Diseases
- Trial name
- CLARITY 2 (NCT05728944)
- Testing
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- LENZ Therapeutics, Inc
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research
Leber Hereditary Optic Neuropathy
RESCUE and REVERSE Long-term Follow-up
The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in…
- Trial name
- RESTORE (NCT03406104)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 62 people
- Sponsor
- GenSight Biologics
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Blindness
Young Blind Child Melatonin Treatment Study
The primary goal of this study is to identify the presence of desynchronized circadian rhythms in 25 children by measuring melatonin secretion in serial blood or saliva samples, and to rule out any primary sleep disorders.
- Trial name
- NCT00688935
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Oregon Health and Science University
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Cataract, Retinal Edema
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
- Conditions
- Cataract, Retinal Edema, Inflammation
- Trial name
- QD (NCT01847638)
- Testing
- Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Melissa Toyos